10-K: Titan Pharmaceuticals Reports FY2024 Results, Focuses on Merger with TalenTec

Titan Pharmaceuticals reports its financial results for the year ended December 31, 2024, highlighting a net loss and ongoing efforts to complete a merger with TalenTec Sdn. Bhd.

Summary

• Titan Pharmaceuticals, Inc. reported a net loss of $4.7 million for the year ended December 31, 2024, compared to a net loss of $5.6 million for the previous year.
• The company's cash used in operating activities was $3.9 million for 2024, a decrease from $7.1 million in 2023.
• As of December 31, 2024, Titan had cash of $2.8 million and working capital of $2.4 million.
• The company is currently focused on completing a merger with TalenTec Sdn. Bhd., a transaction that is subject to stockholder approval and Nasdaq listing requirements.
• Titan sold its ProNeura assets to Fedson, Inc. in September 2023 for $2.0 million plus potential milestone payments and royalties.
• Several executive and board member resignations occurred in April 2024, resulting in approximately $1.2 million in settlement payments.
• The company appointed Chay Weei Jye as Chief Executive Officer in December 2024.
• Titan identified a material weakness in its internal control over financial reporting as of December 31, 2023, which management believes has been remediated as of December 31, 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has made progress in remediating internal control weaknesses and reducing operating costs, it continues to incur net losses and faces significant challenges in securing additional funding and completing the merger with TalenTec. The executive resignations and ongoing need for financing contribute to a negative outlook.

Positives

• The company successfully remediated a material weakness in its internal control over financial reporting.
• Titan's cash used in operating activities decreased from $7.1 million in 2023 to $3.9 million in 2024.
• The company completed the sale of its ProNeura assets, generating $2.0 million in proceeds.
• Titan is actively pursuing a merger with TalenTec, which could provide new opportunities.

Negatives

• Titan Pharmaceuticals incurred a net loss of $4.7 million in FY2024.
• The company's cash and working capital decreased compared to the previous year.
• Several executive and board member resignations occurred, requiring significant settlement payments.
• The company is dependent on the successful completion of the merger with TalenTec.

Risks

• The company's ability to continue as a going concern is dependent on securing additional funding and completing the merger with TalenTec.
• Failure to maintain Nasdaq listing standards could result in delisting of the company's common stock.
• The proposed merger with TalenTec is subject to stockholder and regulatory approvals, and there is no guarantee that it will be completed.
• The company is dependent on the success of the merger with TalenTec.
• The company currently does not have a full-time CFO.

Future Outlook

The company expects to continue to incur net losses and negative operating cash flow for the foreseeable future and will require additional funds to finance its operations. The company is exploring several financing and strategic alternatives; however, there can be no assurance that its efforts will be successful.

Management Comments

• Seow Gim Shen notified our Board of Directors of his decision to resign as Chief Executive Officer and Chairman of the Board of the Company for personal reasons and not as a result of any disagreement with our Board or management on any matter relating to our operations, policies or practices.
• We anticipate that the resignation of Mr. Seow will not impact the Merger Closing with TalenTec.

Industry Context

The pharmaceutical and biotechnology industries are characterized by rapidly evolving technology and intense competition. The company's product development programs are currently in non-clinical stages of development and once these commence clinical development the company can assess and provide details on specific competitive environment.

Management Changes

Related Party Transactions

• In July 2023, the company received $250,000 in funding in exchange for the issuance of an unsecured promissory note to David E. Lazar, the company's Chief Executive Officer and prior chairman of the Board.
• In August 2023, the company received $500,000 in funding in exchange for the issuance of the Hau Promissory Note.
• In September 2023, the company entered into a Securities Purchase Agreement with Sire Group, pursuant to which the company agreed to issue 950,000 shares of its Series AA Preferred Stock to Sire Group at a price of $10.00 per share, for an aggregate purchase price of $9.5 million.
• During the years ended December 31, 2024 and 2023, the company made payments related to legal and consulting fees of approximately $13,000 and $109,000, respectively, to a law firm operated by one of the company's Board members.
• During the year ended December 31, 2024, the company made payments totalling approximately $ 62,000 on behalf of BSKE, a related party.

Stakeholder Impact

• Shareholders face uncertainty due to the company's financial losses and dependence on the successful completion of the merger.
• Employees have been impacted by workforce reductions and executive resignations.
• The company's ability to develop and commercialize new products is dependent on securing additional funding and completing the merger.

Next Steps

• The company will continue to work towards completing the merger with TalenTec Sdn. Bhd.
• The company will seek to secure additional funding to finance its operations.
• The company intends to schedule an annual meeting of shareholders and to submit a plan designed to regain compliance in accordance with the requirements of the Notice and the Nasdaq listing standards.

Key Dates

Keywords

TalenTec, Merger, ProNeura, Financial Results, Titan Pharmaceuticals, TTNP